HC Wainwright & Co. analyst Edward White downgrades ChemoCentryx (NASDAQ:CCXI) from Buy to Neutral and lowers the price target from $101 to $52.
HC Wainwright & Co. Downgrades ChemoCentryx to Neutral, Lowers Price Target to $52
HC Wainwright & Co. analyst Edward White downgrades ChemoCentryx (NASDAQ:CCXI) from Buy to Neutral and lowers the price target from $101 to $52.
Related Posts
Psyched: Full-Dose & Microdosing LSD Studies, Research Scope For Fed Funding, Consumption Sites And More
LSD Research Ramps Up: Full-Dose & Microdosing For Alzheimer's Studies Led By Beckley Foundation Coming Soon
Zhongchao Inc. Announces Strategic Cooperation With Ximalaya
Zhongchao Inc. (NASDAQ:ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that
BMO Capital Maintains Market Perform on Keyera, Lowers Price Target to C$33.5
BMO Capital analyst Ben Pham maintains Keyera (TSX:KEY) with a Market Perform and lowers the price target from C$34 to C$33.5.